Trial Profile
A Phase Ib, Double-Masked, Multiple-Ascending Dose Trial to Evaluate an Eye Drop Formulation of AKB-9778 for Treatment of Primary Open Angle Glaucoma (POAG)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Jul 2020
Price :
$35
*
At a glance
- Drugs Razuprotafib (Primary) ; Prostaglandins
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions
- Sponsors Aerpio Pharmaceuticals
- 07 Feb 2020 According to an Aerpio Pharmaceuticals media release, data from the fifth cohort of subjects were presented at the Glaucoma 360 New Horizons Forum 2020.
- 08 Jan 2020 Results from the additional fifth cohort published in the Aerpio Pharmaceuticals media release.
- 08 Jan 2020 According to an Aerpio Pharmaceuticals media release, based on favorable tolerability and pharmacodynamic findings in ocular normotensive subjects (results declared on October 10, 2019), Aerpio elected to recruit a fifth cohort (n=43) of subjects with ocular hypertension /primary open angle glaucoma on standard of care prostaglandin therapy to assess the safety, tolerability and pilot efficacy of once-daily AKB-9778 (40 mg/ml) as an adjunctive therapy.